AstraZeneca vs GlaxoSmithKline: Pharma stocks to keep an eye on

Be the First to Comment Read

AstraZeneca vs GlaxoSmithKline: Pharma stocks to keep an eye on

 AstraZeneca vs GlaxoSmithKline: Pharma stocks to keep an eye on
Image source: rafapress, Shutterstock.com

Highlights

  • Glaxo’s Daprodustat get FDA approval for the treatment of anaemia in patients suffering from chronic kidney disease.
  • AstraZeneca has recently been granted ‘Priority Review’ status for its drug Enhertu, after the successful completion of its clinical trial. 

Leading British pharmaceutical company GlaxoSmithKline plc (LON: GSK) has been in the limelight lately after securing triumph for its drug with US regulator Food and Drug Administration (FDA) in relation to the treatment of anaemia in patients suffering from chronic kidney disease.

AZN and GSK get drug approvals by US regulator

2022 Kalkine Media®

Glaxo’s Daprodustat, which is the drug that got approved in the US, has successfully completed its phase III clinical trial. The drug is offered in Japan already, and this recent US approval has come after its application for authorisation was acknowledged by the European Medicines Agency in the previous month.

RELATED READ: FTSE 100 trades in red while commodity-focused stocks rise

GSK’s success and performance update

In 2021, the new and speciality drug division of GlaxoSmithKline was the best performing segment in the overall business, making sales of around £10 billion. The newly approved drug, Daprodustat, is a part of the same division. In the clinical trials for Daprodustat, the results were promising for patients on dialysis as well as for those who were not.

The trials continued for over four years and included over 8,000 patients. The drug would play an important role in treating anaemia, which is often hard to detect in chronic kidney disease and impacts around 700 million people globally.

GlaxoSmithKline plc, which is a constituent of the FTSE 100 index, has provided its shareholders with a return of 31.51% over the last one year as of 19 April 2020, while its return on a year-to-date basis stands at 9.52%. The market cap of the company stands at £90,137.51 million as of 19 April 2022. Shares in GlaxoSmithKline closed at GBX 1,759.60, down by 0.76%, on 19 April 2022.

RELATED READ: Greencoat UK Wind, Renewable Infrastructure: Should you buy these stocks now?

GSK vs AZN

British pharma company AstraZeneca plc (LON: AZN) has recently been granted ‘Priority Review’ status for its drug Enhertu, after the successful completion of its clinical trial. The company has created this drug with Japan’s Daiichi Sankyo. The drug focuses on treating patients with lung cancer, who have tumours with a HER2 mutation.

 AZN and GSK get drug approvals by US regulator

2022 Kalkine Media®

As per the recent results released by AstraZeneca, sales of US$214 million were reported by Enhertu last year. If it gets approved fully soon, then its annual sales may potentially jump up to US$1 billion. As per AstraZeneca, Enhertu helps in treating lung cancer in patients with poor diagnosis, who tend to not live beyond five years after the detection of cancer.

AstraZeneca plc, which is a constituent of the FTSE 100 index, has provided its shareholders with a return of 41.62% over the last one year as of 19 April 2020, while its return on a year-to-date basis stands at 21.00%. The market cap of the company stands at £163,250.46 million as of 19 April 2022. Shares in AstraZeneca plc closed at GBX 10,500.00, down by 0.34%, on 19 April 2022.

Note: The above content constitutes a very preliminary observation or view based on market trends and is of limited scope without any in-depth fundamental valuation or technical analysis. Any interest in stocks or sectors should be thoroughly evaluated taking into consideration the associated risks.

Disclaimer

Speak your Mind

Featured Articles